Verenium Corporation reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2009. Total revenues for the third quarter ended September 30, 2009 were $18.6 million compared to $16.4 million for the same period in the prior year. Net loss attributed to Verenium for the quarter was $2.3 million, or $0.25 loss per basic and diluted share compared to $126.1 million, or $22.98 loss per basic and diluted share for the same period in 2008. Adjusted for the non-cash impact of accounting related to the 8% and 9% convertible notes and non-cash goodwill impairment charge, the company's non-GAAP pro-forma net loss for the quarter was $10.5 million, or $1.16 loss per basic and diluted share, as compared to $19.5 million, or $3.55 loss per basic and diluted share for the same period in the prior year. Loss from operations was $16.6 million against $128.3 million for the same period in the prior year. Net loss was $11.0 million against $131.1 million for the same period in the prior year. Total revenues for the nine months ended September 30, 2009 were $49.3 million, compared to $49.9 million for the same period in the prior year. Net loss attributed to Verenium for the nine months ended September 30, 2009 was $18.9 million, or $2.54 loss per basic and diluted share compared to $164.6 million, or $31.28 loss per basic and diluted share for the same period in 2008. Adjusted for the non-cash impact of accounting related to the 8% and 9% convertible notes and non-cash goodwill impairment charge, the company's non-GAAP pro-forma net loss was $36.6 million, or $4.90 loss per basic and diluted share against $56.0 million, or $10.65 loss per basic and diluted share for the nine months ended September 30, 2008. Loss from operations was $53.1 million against $160.8 million for the same period in the prior year. Net loss was $44.4 million against $169.6 million for the same period in the prior year.

Verenium Corporation expected to Report Fiscal Year 2009 Results on February 22, 2010. This event was calculated by Capital IQ (Created on November 9, 2009).

Verenium Corporation announced the successful closure of previously defined programs under its joint research collaboration with Syngenta Participations AG of Switzerland. In connection with the completion of those programs, the parties have executed an agreement whereby Verenium gained additional exclusive rights to an array of proprietary biomolecules expressed microbially, as well as non-exclusive rights to the same biomolecules expressed through non-plant and non-microbial means, further bolstering its strong Specialty Enzymes product pipeline. Syngenta will retain exclusive rights to the biomolecules expressed in plants, as well as nonexclusive rights to the same biomolecules expressed through non-plant, non-microbial means.